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Purpose
Acute myeloid leukemia (AML) in elderly patients has a poor prognosis. In an
attempt to improve outcome for these patients, the prospective open-label phase III
LAM-SA 2007 (Adding Lomustine to Chemotherapy in Older Patients With Acute
Myelogenous Leukemia (AML), and Allogeneic Transplantation for Patients From 60
to 65 Years Old) trial randomly assigned patients to a standard induction regimen
with lomustine added or to a consolidation regimen with cytarabine and idarubicin.
Patients and Methods
Adults age 60 years or older with previously untreated AML who were fit to receive
intensive chemotherapy and who were without unfavorable cytogenetics received
standard chemotherapy with lomustine (idarubicin, cytarabine, and lomustine [ICL])
or without (idarubicin and cytarabine [IC]). The primary objective of the study was
overall survival (OS); secondary objectives were response rate, cumulative incidence
of relapse (CIR), event-free survival (EFS), and safety.
Results
From February 2008 to December 2011, 459 patients were enrolled. Comparing
patients in the IC and ICL arms, complete response or complete response with
incomplete recovery was achieved in 74.9% versus 84.7% (P = .01). The
proportional hazards assumption was rejected for OS (P = .02), which led us to
consider two separate time intervals: during and after induction. There was no
significant difference between the two arms during induction, although induction
deaths were 3.7% versus 7.7%, respectively (P = .11). However, significantly better
results were observed after induction with an improved 2-year OS of 56% in the ICL
arm versus 48% in the IC arm (P = .02). At 2 years, EFS was improved at 41% in the
ICL arm versus 26% in the IC arm (P = .01). The CIR at 2 years was 41.2% in the
ICL arm versus 60.9% in the IC arm (P = .003). Grade 3 and 4 toxicities, mostly
hematologic, were significantly higher in the ICL arm (P = .04), and fewer patients
required a second treatment after ICL.
Conclusion
Adding lomustine to standard chemotherapy significantly improved the outcome of
elderly patients with AML.
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